Therapy with an antiarrhythmic drug that renders VT/VF noninducible is associated with a more favorable outcome than drug therapy during which VT/VF remains inducible. [3] [4] [5] This invasive approach selects therapy that prevents sustained VT/VF better than does the noninvasive approach of suppression of spontaneous ventricular arrhythmia.67 However, the invasive approach does have certain limitations. The probability of finding effective drug therapy during serial electropharmacological trials is low: 23%, 9%, and 8% at the first, second, and third drug trials, respectively.8 Effective antiarrhythmic drugs can be identified for no more than 40-50% of these patients.9-"1 Furthermore, multiple electropharmacological studies can be time consuming and have inherent risks.12 Thus, before undertaking a series of electropharmacological trials, it would be useful to know which patients are likely or unlikely to respond.
Previous studies have indicated that certain patient and electrophysiological characteristics are associated with a higher probability of successful outcome. [13] [14] [15] [16] However, the effect of infarct-related artery (IRA) patency on the outcome of serial electropharmacological studies has not been studied previously. It is possible that antiarrhythmic drug delivery would be greater to the arrhythmogenic substrate in the peri-infarct zone with a patent IRA than with an occluded IRA. We hypothesized that the probability of finding effective drug therapy would be greater in patients with a patent IRA than in those with an occluded IRA. Accordingly, the purpose of the present study was to assess whether the outcome of serial electropharmacological studies in a patient with sustained VT/VF is related to the patency of the IRA.
Methods

Patients
Patients with sustained VT/VF that was not due to reversible causes were considered potential candidates for this study. Patients were eligible when they met all of the following inclusion criteria: 1) coronary artery disease and history of remote mypcardial infarction, 2) spontaneous and inducible sustained VT/VF at a baseline antiarrhythmic drug-free electrophysiological study, 3) serial electropharmacological studies were performed, and 4) cardiac catheterization and coronary angiography were performed. Hemodynamic and Angiographic Assessment Cardiac catheterization and coronary angiography were performed before electrophysiological study. An 
Results
Patient Characteristics
We identified 64 consecutive patients who fulfilled all the four inclusion criteria as listed in "Methods." This study group is characterized in Table 1 . These patients were generally men with low LVEF. Most of the patients had at least two-vessel coronary artery disease. All patients had a history of remote myocardial infarction. Only nine patients (14%) had suffered two previous myocardial infarctions. The remaining 55 patients had a single previous myocardial infarction.
Responders and Nonresponders to Drug Therapy
Effective antiarrhythmic drug therapy could be identified for 16 patients (25%). The clinical characteristics of responders and nonresponders are shown in Table 2 . There were no significant differences in patient demographics between responders and nonresponders. As expected, nonresponders had undergone a greater number of electropharmacological studies compared with responders (4±2 versus 2+1, p=0.005). None of the electrocardiographic or angiographic measures were significantly different between responders and nonresponders. However, no effective drug therapy could be identified for all 10 patients with left ventricular aneurysm (p<0.06). The VT cycle length was similar in responders (273±75 msec) and nonresponders (261±45 msec). However, the VT cycle length was shorter in patients presenting with VF (231±33 msec) compared with those presenting with VT (276±55 msec, p<0.05).
Hemodynamic Data Table 3 shows the hemodynamic data for responders and nonresponders. No significant differences were found in the hemodynamic measurements between responders and nonresponders.
Electrophysiological Data
Electrophysiological measurements obtained at baseline and during serial electropharmacological studies for responders and nonresponders are presented in Table 4 . At baseline, responders and nonresponders did not differ significantly in their ventricular effective refractory periods at any of the three pacing cycle lengths. Responders had longer ventricular functional refractory periods than nonresponders, although these differences were only statistically significant at a pacing cycle length of 500 msec (p=0.02). During serial electropharmacological studies, responders tended to have longer ventricular effective and functional refractory periods than nonresponders, but these differences were only significant at pacing cycle length of 500 msec (Table 4) (Figure 1 ). This difference was highly statistically significant (p=0.001). Effective drug therapy could be identified for five of the six patients whose IRAs were revascularized. To assess this relation in a more homogeneous patient group, the data were analyzed separately for the 52 patients who had only one previous myocardial infarction and sustained monoform VT induced at the baseline electrophysiological study. Three patients with inducible VF and nine patients with two infarction sites were excluded from this analysis. Ten of 23 patients (44%) with a patent IRA were Data are mean± 1 SD. VF, ventricular fibrillation; VT, ventricular tachycardia; LVEF, left ventricular ejection fraction; IVCD, intraventricular conduction delay; IRA, infarct-related artery.
responders compared with only three of the 29 patients (10%) with an occluded IRA (p=0.009) (Figure 1 patients with patent and occluded IRAs (Table 6) .
Similarly, the ventricular refractory periods measured during antiarrhythmic therapy were similar in patients with patent and occluded IRAs. Antiarrhythmic druginduced changes in the ventricular effective refractory period tended to be higher in patients with a patent IRA, but this difference was only statistically significant at a pacing cycle length of 600 msec (p<0.005).
Predictive Value of IRA Patency Status
Stepwise logistic regression analysis was applied to univariate predictors of antiarrhythmic drug response. Patency of the IRA was the only independent predictor of successful suppression of VT/VF induction during electrophysiological studies (p=0.004). The predictive value of a patent IRA in the study population is shown in Table 7 . In the whole study group, a patent IRA had a sensitivity of 81% and specificity of 67% for the prediction of successful electropharmacological studies. The overall positive and negative predictive values of a patent IRA were 45% and 91%, respectively. The sensitivity and specificity of a patent IRA were 77% and 67%, respectively, when only patients with sustained VT and 
Conclusions
This study assessed the effect of IRA patency on the outcome of electropharmacological studies in patients with VT/VF in the setting of remote myocardial infarction. Our findings demonstrate that successful electropharmacological studies are more likely in patients with a patent IRA. An occluded IRA is associated with a very low probability of finding effective drug therapy. This information can be used to stratify patients as potential drug responders or nonresponders at an early stage. Furthermore, the results of this study suggest that coronary artery revascularization should be considered in patients with an occluded coronary artery presenting with VT/VF before embarking on electropharmacological testing. Future studies will be needed to address this hypothesis.
